Gallbladder Cancer
Conditions
Keywords
diagnosis
Brief summary
Copy number variation(CNV) refers to ongoing chromosome segregation errors throughout consecutive cell divisions. CNV is a hallmark of human cancer, and it is associated with poor prognosis, metastasis, and therapeutic resistance. Analyzing CNV of the DNA extracted from bile samples in gallbladder seems a promising method for diagnosing, monitoring, and predicting the prognosis of patients with gallbladder cancer. CNV can be assessed using experimental techniques such as bulk DNA sequencing, fluorescence in situ hybridization (FISH), or conventional karyotyping. However, these techniques are either time-consuming or non-specific. The investigators here intend to study whether a new method named Ultrasensitive Chromosomal Aneuploidy Detection (UCAD), which is based on low-coverage whole-genome sequencing, can be used to analyze CNV thus helping diagnose gallbladder cancer and assessing follow-up.
Interventions
DIAGNOSTIC_TESTThe level of CNV
The extracted DNA from bile will be analyzed by UCAD to determine the level of CNV. And the patient will be followed more than 1 year.
Sponsors
Shanghai Zhongshan Hospital
Ruijin Hospital
Changhai Hospital
Shanghai Changzheng Hospital
Eastern Hepatobiliary Surgery Hospital
First Affiliated Hospital Xi'an Jiaotong University
Jiangsu Provincial People's Hospital
Third Affiliated Hospital, Sun Yat-Sen University
First Affiliated Hospital of Zhejiang University
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Second Hospital of Jilin University
West China Hospital
Southwest Hospital, China
Affiliated Hospital of North Sichuan Medical College
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients diagnosed with gallbladder disease and planned to undergo surgery. * Male or female patients aged \>= 18 years. * Participants signed informed consent form.
Exclusion criteria
* Participants had other tumor expect gallbladder cancer
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| UCAD can be used as a diagnostic technology for gallbladder cancer with the sensitivity more than 90% | 2025 | Ultrasensitive chromosomal aneuploidy detection (UCAD) uses low-coverage whole-genome sequencing technology to detect DNA chromosomal instability in samples. By detecting DNA extracted from patients' bile and blood, bioinformatics can be used to analyze the differences in CNV between benign and malignant gallbladder diseases, and a prediction model for gallbladder cancer. |
Countries
China
Outcome results
None listed